Stockscreener 앱 받기
8.82
0.23%
-0.02
시간 외 거래:
8.82
전일 마감가:
$8.84
열려 있는:
$8.92
하루 거래량:
324.84K
Relative Volume:
1.16
시가총액:
$463.87M
수익:
$2.22M
순이익/손실:
$-40.51M
주가수익비율:
-6.8654
EPS:
-1.2847
순현금흐름:
$-46.53M
1주 성능:
+2.08%
1개월 성능:
+35.07%
6개월 성능:
-66.31%
1년 성능:
+0.00%
1일 변동 폭
$8.53
$9.40
1주일 범위
$7.79
$9.40
52주 변동 폭
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
명칭
Upstream Bio Inc
전화
781-208-2466
주소
890 WINTER STREET, SUITE 200, WALTHAM
UPB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
8.82 | 463.87M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
Upstream Bio Inc 주식(UPB)의 최신 뉴스
Is Upstream Bio Inc (NASDAQ: UPB) A Good Investment Now? - Stocksregister
Wells Fargo & Company MN Invests $149,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
27,017 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Acquired by Barclays PLC - Defense World
MetLife Investment Management LLC Invests $181,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Brokers Offer Predictions for Upstream Bio Q2 Earnings - Defense World
Metric Analysis: Upstream Bio Inc (UPB)’s Key Ratios in the Limelight - DWinneX
Upstream Bio Advances Verekitug in Clinical Trials - TipRanks
Upstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial Position - TipRanks
Upstream Bio reports Q1 revenue $566k, consensus $326.25k - TipRanks
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs - GlobeNewswire
Transpire Bio Announces R&D and Manufacturing Expansion - The Manila Times
Upstream Bio Fast-Tracks Clinical Trials: Key Data Coming Earlier for Revolutionary Respiratory Drug - Stock Titan
Invesco Ltd. Buys Shares of 15,602 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
1,734 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Legal & General Group Plc - Defense World
JPMorgan Chase & Co. Acquires Shares of 47,792 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
LPL Financial LLC Cuts Stake in Invesco FTSE RAFI Developed Markets ex-U.S. Small-Mid ETF (NYSEARCA:PDN) - Defense World
Geode Capital Management LLC Purchases New Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Upstream Bio Inc’s Banking’s 100-Day Moving Average at 11.87: Will the Stock Break Through? - investchronicle.com
Medical Properties Trust Inc (MPW) Stock: Navigating a Year of Volatility - investchronicle.com
CytomX Therapeutics Inc’s Shares Reel: -10.73% Quarterly Revenue Decline Amid 60.07M Market Cap - investchronicle.com
Philip Morris International Inc (PM) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Upstream Bio: Verekitug, A Longer-Acting Dupixent?Key Data Is Imminent - Seeking Alpha
Corebridge Financial Inc. Takes Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by American Century Companies Inc. - Defense World
Old Dominion Freight Line (NASDAQ:ODFL) Given New $188.00 Price Target at Stifel Nicolaus - Defense World
Chronic Rhinosinusitis with Nasal Polyps Market to Expand Significantly by 2034, States DelveInsight Report | AstraZeneca, Amgen, Keymed Biosciences, GlaxoSmithKline, Genentech, Inc, Novartis - Barchart.com
Upstream Bio (NASDAQ:UPB) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Amtech Systems, Tesla And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Upstream's IPO Lockup Period Expires, RSLS Partners With Israel-based Motion, PVLA On Watch - RTTNews
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket - Benzinga
Certain Common Stock of Upstream Bio, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2025. - marketscreener.com
Upstream Bio, Inc.’s Lock-Up Period Will Expire on April 9th (NASDAQ:UPB) - Defense World
Charles Schwab Investment Management Inc. Invests $2.23 Million in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Bank of New York Mellon Corp Invests $607,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Severe Asthma Clinical Trials and Studies 2025: EMA, PDMA, FDA - openPR.com
Upstream Bioprocessing Market Size, Industry Demand And Report Insights By 2033 - Straits Research
1,660 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Acquired by US Bancorp DE - Defense World
US Bancorp DE Sells 4,285 Shares of SunOpta Inc. (NASDAQ:STKL) - The AM Reporter
Upstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial Execution - TipRanks
William Blair Lifts Earnings Estimates for Upstream Bio - Defense World
Long UPB: Upstream Bio’s Robust Financials and Clinical Progress Signal Bullish Reversal - Invezz
Upstream Bio’s Financial Results and Strategic Progress - TipRanks
Promising Developments and Strong Financial Position Drive Buy Rating for Upstream Bio, Inc. - TipRanks
Buy Rating for Upstream Bio: Promising Clinical Progress and Unique Drug Candidate Potential - TipRanks
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Form 10-K Upstream Bio, Inc. For: Dec 31 - StreetInsider.com
Upstream Bio, Inc. Completes Enrollment in Phase 2 Trial of Verekitug for Chronic Rhinosinusitis and Raises $293 Million in IPO - Nasdaq
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business ... - Enid News & Eagle
Rhumbline Advisers Invests $275,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
AstraZeneca And GSK Put Spotlight On Nasal Polyps Space - Citeline News & Insights
Upstream Bio Inc (UPB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.15%
자본화:
|
볼륨(24시간):